- Home
- CEPU vs DNLI Comparison
CEPU vs DNLI Comparison
Compare CEPU & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- DNLI
- Stock Information
- Founded
- CEPU 1989
- DNLI 2013
- Country
- CEPU Argentina
- DNLI United States
- Employees
- CEPU N/A
- DNLI N/A
- Industry
- CEPU Electric Utilities: Central
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEPU Utilities
- DNLI Health Care
- Exchange
- CEPU Nasdaq
- DNLI Nasdaq
- Market Cap
- CEPU 1.8B
- DNLI 2.1B
- IPO Year
- CEPU 2018
- DNLI 2017
- Fundamental
- Price
- CEPU $11.51
- DNLI $14.78
- Analyst Decision
- CEPU Hold
- DNLI Strong Buy
- Analyst Count
- CEPU 1
- DNLI 16
- Target Price
- CEPU $12.00
- DNLI $37.57
- AVG Volume (30 Days)
- CEPU 231.8K
- DNLI 1.3M
- Earning Date
- CEPU 03-11-2025
- DNLI 05-06-2025
- Dividend Yield
- CEPU 2.68%
- DNLI N/A
- EPS Growth
- CEPU N/A
- DNLI N/A
- EPS
- CEPU 0.03
- DNLI N/A
- Revenue
- CEPU $715,974,448.00
- DNLI N/A
- Revenue This Year
- CEPU $29.08
- DNLI N/A
- Revenue Next Year
- CEPU N/A
- DNLI $497.02
- P/E Ratio
- CEPU $44.04
- DNLI N/A
- Revenue Growth
- CEPU 8.10
- DNLI N/A
- 52 Week Low
- CEPU $7.07
- DNLI $13.67
- 52 Week High
- CEPU $16.60
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CEPU 40.14
- DNLI 39.87
- Support Level
- CEPU $11.95
- DNLI $13.67
- Resistance Level
- CEPU $12.60
- DNLI $14.90
- Average True Range (ATR)
- CEPU 0.69
- DNLI 0.76
- MACD
- CEPU 0.02
- DNLI 0.15
- Stochastic Oscillator
- CEPU 16.25
- DNLI 42.53
Stock Price Comparison Chart: CEPU vs DNLI
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a private-sector power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.